It’s true that you never realise how precious time is, until it runs out.

Devastatingly, it's something Smiddy rider and triathlete Serge knows only too well. He lost his beloved wife Emma after three years fighting melanoma.

She was just 25 years old.

 

Story image

You can give the gift of time

In the three years before her passing Emma committed herself to raising awareness of melanoma and raising funds for research. She raised over $100 000.

Now Serge has taken on her legacy, raising funds for cancer research at Mater through Smiling for Smiddy.

As he says:

"It's so important for people to donate to Smiling for Smiddy. Your donations really do help fund the research and can help pave the way for new treatments.

Cancer research gave Emma more treatment options compared to those diagnosed with Stage 4 melanoma a couple of years earlier. More treatment options gave Emma and I more time together. More time together allowed us to make more memories."

The Smiling for Smiddy story

In 2006, Adam Smiddy passed away from an aggressive melanoma. From the time of his initial diagnosis until his passing he had just six months with his family and friends.

He was only 26 years old.

At the time of his diagnosis, the long-term survival rate, which is five years, for those diagnosed with melanoma was 15 per cent—and they were a very lucky 15 per cent.

In the 12 years since Adam’s passing, research—like that you can help fund through Smiling for Smiddy—has boosted the long-term survival rate.

Because of people like you, families like Serge and Emma have been given more time together.

They were able to turn three short months, into three years of incredible memories.

But there’s still so much more to be done, and we need your help.

Story image

How you can help

By donating to Smiling for Smiddy today you'll be helping to fund life-saving research into melanoma as well as prostate, breast and ovarian cancer research at Mater.

Research like that being conducted by Professor Brian Gabrielli at Mater Research.

He and his team are looking into the interactions between an existing 'old fashioned' drug and one that has been recently developed, to see how they can be combined to  increase the number of melanomas that respond.

"We're now testing how effective it is in pre-clinical models; how broadly effective it may be and whether there are markers that can help us identify patients who could benefit most from this drug combination.

It's definitely a more personalised approach to treating cancer." Prof Gabrielli said.

Meet our partners

Thank you to our partners. We couldn't do it without you!